Mechanistically, mutant KRAS upregulates SG formation by stimulating the production of prostaglandin 15-d-PGJ2 which enables paracrine control of SG, eventually resulting in resistance of cancer cells to stress stimuli (Grabocka and Bar-Sagi, 2016). The gene discussed is KRAS; the disease is cancer.